Download PDF
Semin Reprod Med 2010; 28(2): 126-132
DOI: 10.1055/s-0030-1248137
© Thieme Medical Publishers

Injectable Contraception

Geneviève Roy1
  • 1Department of Obstetrics and Gynecology, University of Montreal, Montréal, Québec, Canada
Further Information

Publication History

Publication Date:
29 March 2010 (online)

    Permissions and Reprints

ABSTRACT

Injectable contraception has many advantages and is a popular birth control method worldwide. Its efficacy is independent of a daily action or an intervention around the time of coitus. It is highly efficacious and well tolerated in general. In the United States, the available injectable contraceptive is depot medroxyprogesterone acetate (DMPA). Its use is associated with a decrease in bone mineral density (BMD) that is largely if not completely reversible over time and very comparable to the BMD loss associated with pregnancy and breastfeeding. The available knowledge on the impact of BMD loss on the risks of fractures later in life is incomplete, but in the light of the small magnitude of impact of DMPA on BMD and its reversibility, any increase in the risk of osteoporotic fractures is likely to be small. This article reviews the recent evidence on DMPA's efficacy, risks and benefits, and side effects with a focus on bone health issues.

KEYWORDS

Injectable contraception - depot medroxyprogesterone acetate - Depo-Provera - medroxyprogesterone acetate

REFERENCES

  • 1 Paschall S, Kaunitz A M. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.  Contraception. 2008;  78(5) 370-376
    CrossrefPubMedGoogle Scholar
  • 2 Mishell Jr D R. Pharmacokinetics of depot medroxyprogesterone acetate contraception.  J Reprod Med. 1996;  41(5, Suppl) 381-390
    PubMedGoogle Scholar
  • 3 Prabhakaran S. Self-administration of injectable contraceptives.  Contraception. 2008;  77(5) 315-317
    CrossrefPubMedGoogle Scholar
  • 4 Kaunitz A M. Long-acting injectable contraception with depot medroxyprogesterone acetate.  Am J Obstet Gynecol. 1994;  170(5 Pt 2) 1543-1549
    PubMedGoogle Scholar
  • 5 Trussell J. Contraceptive failure in the United States.  Contraception. 2004;  70 89-96
    CrossrefPubMedGoogle Scholar
  • 6 Jain J, Jakimiuk A J, Bode F R, Ross D, Kaunitz A M. Contraceptive efficacy and safety of DMPA-SC.  Contraception. 2004;  70(4) 269-275
    CrossrefPubMedGoogle Scholar
  • 7 Petta C A, Faundes A, Dunson T R et al.. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.  Fertil Steril. 1998;  69(2) 252-257
    CrossrefPubMedGoogle Scholar
  • 8 Lopez L M, Newmann S J, Grimes D A, Nanda K, Schulz K F. Immediate start of hormonal contraceptives for contraception.  Cochrane Database Syst Rev. 2008;  2(2) CD006260
    PubMedGoogle Scholar
  • 9 Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill M S. Pregnancies diagnosed during Depo-Provera use.  Contraception. 2002;  66(3) 169-172
    CrossrefPubMedGoogle Scholar
  • 10 Steiner M J, Kwok C, Stanback J et al.. Injectable contraception: what should the longest interval be for reinjections?.  Contraception. 2008;  77(6) 410-414
    CrossrefPubMedGoogle Scholar
  • 11 Belsey E M. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation.  Adv Contracept. 1991;  7(2–3) 257-270
    CrossrefPubMedGoogle Scholar
  • 12 Kaunitz A M. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.  J Reprod Med. 1996;  41(5, suppl) 419-427
    PubMedGoogle Scholar
  • 13 Cullins V E. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.  J Reprod Med. 1996;  41(5, suppl) 428-433
    PubMedGoogle Scholar
  • 14 Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani P G. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.  Am J Obstet Gynecol. 1996;  175(2) 396-401
    CrossrefPubMedGoogle Scholar
  • 15 Crosignani P G, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain.  Hum Reprod. 2006;  21(1) 248-256
    CrossrefPubMedGoogle Scholar
  • 16 Schlaff W D, Carson S A, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.  Fertil Steril. 2006;  85(2) 314-325
    CrossrefPubMedGoogle Scholar
  • 17 De Ceulaer K, Gruber C, Hayes R, Serjeant G R. Medroxyprogesterone acetate and homozygous sickle-cell disease.  Lancet. 1982;  2(8292) 229-231
    PubMedGoogle Scholar
  • 18 Mattson R H, Cramer J A, Caldwell B V, Siconolfi B C. Treatment of seizures with medroxyprogesterone acetate: preliminary report.  Neurology. 1984;  34(9) 1255-1258
    PubMedGoogle Scholar
  • 19 Frederiksen M C. Depot medroxyprogesterone acetate contraception in women with medical problems.  J Reprod Med. 1996;  41(5, suppl) 414-418
    PubMedGoogle Scholar
  • 20 North American Menopause Society . Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.  Menopause. 2004;  11(1) 11-33
    CrossrefPubMedGoogle Scholar
  • 21 Thomas D B, Ray R M. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer.  Int J Cancer. 1991;  49(2) 186-190
    PubMedGoogle Scholar
  • 22 WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Breast cancer and depot-medroxyprogesterone acetate: a multinational study.  Lancet. 1991;  338(8771) 833-838
    CrossrefPubMedGoogle Scholar
  • 23 The WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer.  Int J Cancer. 1991;  49(2) 191-195
    PubMedGoogle Scholar
  • 24 The WHO Collaborative Study of Neoplasia and Steroid Contraceptives . Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer.  Contraception. 1992;  45(4) 299-312
    CrossrefPubMedGoogle Scholar
  • 25 Skegg D C, Noonan E A, Paul C et al.. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of World Health Organization and New Zealand studies.  JAMA. 1995;  273 799-804
    CrossrefPubMedGoogle Scholar
  • 26 Shapiro S, Rosenberg L, Hoffman M et al.. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives.  Am J Epidemiol. 2000;  151(4) 396-403
    PubMedGoogle Scholar
  • 27 Strom B L, Berlin J A, Weber A L et al.. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.  Contraception. 2004;  69(5) 353-360
    CrossrefPubMedGoogle Scholar
  • 28 Schwallie P C, Assenzo J R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review.  Contraception. 1974;  10(2) 181-202
    CrossrefPubMedGoogle Scholar
  • 29 Kahn H S, Curtis K M, Marchbanks P A. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk.  Diabetes Care. 2003;  26(1) 216-225
    CrossrefPubMedGoogle Scholar
  • 30 Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.  J Reprod Med. 1996;  41(5, suppl) 401-406
    PubMedGoogle Scholar
  • 31 Garza-Flores J, De la Cruz D L, Valles de Bourges V et al.. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.  Contraception. 1991;  44(1) 61-71
    CrossrefPubMedGoogle Scholar
  • 32 Enk L, Landgren B M, Lindberg U B, Silfverstolpe G, Crona N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.  Horm Metab Res. 1992;  24(2) 85-89
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Graff-Iversen S, Tonstad S. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey.  Contraception. 2002;  66(1) 7-13
    CrossrefPubMedGoogle Scholar
  • 34 Sorensen M B, Collins P, Ong P J et al.. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.  Circulation. 2002;  106(13) 1646-1651
    CrossrefPubMedGoogle Scholar
  • 35 Kaunitz A M. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.  Circulation. 2003;  107(9) e67-e68; author reply e67–e68
    CrossrefPubMedGoogle Scholar
  • 36 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study.  Contraception. 1998;  57(5) 315-324
    CrossrefPubMedGoogle Scholar
  • 37 Committee on Practice Bulletins-Gynecology . ACOG practice bulletin. Use of hormonal contraception in women with coexisting medical conditions, number 23.  Obstet Gynecol. 2006;  107(6) 1453-1472
    CrossrefPubMedGoogle Scholar
  • 38 Clark M K, Sowers M, Levy B T, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception.  Fertil Steril. 2001;  75(5) 871-877
    CrossrefPubMedGoogle Scholar
  • 39 Karlsson M K, Ahlborg H G, Karlsson C. Maternity and bone mineral density.  Acta Orthop. 2005;  76(1) 2-13
    PubMedGoogle Scholar
  • 40 Kalkwarf H J. Lactation and maternal bone health.  Adv Exp Med Biol. 2004;  554 101-114
    PubMedGoogle Scholar
  • 41 Kalkwarf H J, Specker B L. Bone mineral changes during pregnancy and lactation.  Endocrine. 2002;  17(1) 49-53
    CrossrefPubMedGoogle Scholar
  • 42 Curtis K M, Martins S L. Progestogen-only contraception and bone mineral density: a systematic review.  Contraception. 2006;  73(5) 470-487
    CrossrefPubMedGoogle Scholar
  • 43 Cromer B A, Bonny A E, Stager M et al.. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study.  Fertil Steril. 2008;  90(6) 2060-2067
    CrossrefPubMedGoogle Scholar
  • 44 Kaunitz A M, Darney P D, Ross D, Wolter K D, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.  Contraception. 2009;  80(1) 7-17
    CrossrefPubMedGoogle Scholar
  • 45 Kaunitz A M, Miller P D, Rice V M, Ross D, McClung M R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.  Contraception. 2006;  74(2) 90-99
    CrossrefPubMedGoogle Scholar
  • 46 Scholes D, LaCroix A Z, Ichikawa L E, Barlow W E, Ott S M. Injectable hormone contraception and bone density: results from a prospective study.  Epidemiology. 2002;  13(5) 581-587
    CrossrefPubMedGoogle Scholar
  • 47 Kaunitz A M, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.  Contraception. 2008;  77(2) 67-76
    CrossrefPubMedGoogle Scholar
  • 48 Rosenberg L, Zhang Y, Constant D et al.. Bone status after cessation of use of injectable progestin contraceptives.  Contraception. 2007;  76(6) 425-431
    CrossrefPubMedGoogle Scholar
  • 49 Kaunitz A M, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.  Contraception. 2008;  77(2) 67-76
    CrossrefPubMedGoogle Scholar
  • 50 Scholes D, LaCroix A Z, Ichikawa L E, Barlow W E, Ott S M. Injectable hormone contraception and bone density: results from a prospective study.  Epidemiology. 2002;  13(5) 581-587
    CrossrefPubMedGoogle Scholar
  • 51 Orr-Walker B J, Evans M C, Ames R W, Clearwater J M, Cundy T, Reid I R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.  Clin Endocrinol (Oxf). 1998;  49(5) 615-618
    CrossrefPubMedGoogle Scholar
  • 52 Cundy T, Cornish J, Roberts H, Reid I R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception.  Am J Obstet Gynecol. 2002;  186(5) 978-983
    CrossrefPubMedGoogle Scholar
  • 53 Scholes D, LaCroix A Z, Ichikawa L E, Barlow W E, Ott S M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.  Arch Pediatr Adolesc Med. 2005;  159(2) 139-144
    CrossrefPubMedGoogle Scholar
  • 54 Schlaff W D, Carson S A, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.  Fertil Steril. 2006;  85(2) 314-325
    CrossrefPubMedGoogle Scholar
  • 55 Crosignani P G, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain.  Hum Reprod. 2006;  21(1) 248-256
    CrossrefPubMedGoogle Scholar
  • 56 World Health Organization . Department of Reproductive Health and Research. WHO statement on hormonal contraception and bone health.  Wkly Epidemiol Rec. 2005;  80 302-304
    PubMedGoogle Scholar
  • 57 The National Collaborating Centre for Women's and Children's Health .Long-Acting Reversible Contraception—Clinical Guideline 30. London, United Kingdom; National Institute for Health and Clinical Excellence 2005: 1-176
    Google Scholar
  • 58 Cromer B A, Scholes D, Berenson A, Cundy T, Clark M K, Kaunitz A M. Society for Adolescent Medicine . Depot medroxyprogesterone acetate and bone mineral density in adolescents—the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.  J Adolesc Health. 2006;  39(2) 296-301
    CrossrefPubMedGoogle Scholar
  • 59 Black A. Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada . Canadian contraception consensus—update on depot medroxyprogesterone acetate (DMPA).  J Obstet Gynaecol Can. 2006;  28(4) 305-313
    PubMedGoogle Scholar
  • 60 Cundy T, Ames R, Horne A et al.. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate.  J Clin Endocrinol Metab. 2003;  88(1) 78-81
    CrossrefPubMedGoogle Scholar
  • 61 Cromer B A, Lazebnik R, Rome E et al.. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception.  Am J Obstet Gynecol. 2005;  192(1) 42-47
    CrossrefPubMedGoogle Scholar
  • 62 Belsey E M. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.  Contraception. 1988;  38(2) 181-206
    CrossrefPubMedGoogle Scholar
  • 63 Kaunitz A M. Menstruation: choosing whether . . . and when.  Contraception. 2000;  62(6) 277-284
    CrossrefPubMedGoogle Scholar
  • 64 Glasier A F, Smith K B, van der Spuy Z M et al.. Amenorrhea associated with contraception—an international study on acceptability.  Contraception. 2003;  67(1) 1-8
    CrossrefPubMedGoogle Scholar
  • 65 Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gulmezoglu A M. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.  Cochrane Database Syst Rev. 2007;  (4) CD003449
    PubMedGoogle Scholar
  • 66 Mainwaring R, Hales H A, Stevenson K et al.. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.  Contraception. 1995;  51(3) 149-153
    CrossrefPubMedGoogle Scholar
  • 67 Moore L L, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.  Contraception. 1995;  52(4) 215-219
    CrossrefPubMedGoogle Scholar
  • 68 Risser W L, Gefter L R, Barratt M S, Risser J M. Weight change in adolescents who used hormonal contraception.  J Adolesc Health. 1999;  24(6) 433-436
    CrossrefPubMedGoogle Scholar
  • 69 Danli S, Qingxiang S, Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women.  Contraception. 2000;  62(1) 15-18
    CrossrefPubMedGoogle Scholar
  • 70 Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women.  Contraception. 2000;  62(2) 55-58
    CrossrefPubMedGoogle Scholar
  • 71 Templeman C, Boyd H, Hertweck S P. Depomedroxyprogesterone acetate use and weight gain among adolescents.  J Pediatr Adolesc Gynecol. 2000;  13(1) 45-46
    CrossrefPubMedGoogle Scholar
  • 72 Mangan S A, Larsen P G, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate.  J Pediatr Adolesc Gynecol. 2002;  15(2) 79-82
    CrossrefPubMedGoogle Scholar
  • 73 Berenson A B, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use.  Am J Obstet Gynecol. 2009;  200(3) 329 , e1–e8
    PubMedGoogle Scholar
  • 74 Schwallie P, Assenzo J R. Conctraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days.  Fertil Steril. 1973;  24(5) 331-339
    PubMedGoogle Scholar
  • 75 Björn I, Bixo M, Nöjd K S, Nyberg S, Bäckström T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens.  Am J Obstet Gynecol. 2000;  183(6) 1419-1426
    CrossrefPubMedGoogle Scholar

Geneviève RoyM.D. M.P.H. F.R.C.S.C. 

Assistant Professor, Department of Obstetrics and Gynecology, University of Montreal CHUM – Hôpital St-Luc

1058, rue Saint-Denis, Montréal, Québec, Canada H2X 3J4

Email: genipou14@hotmail.com; genevieve.roy.chum@ssss.gouv.qc.ca

      >